The financials
Viridian Therapeutics, Inc. by the numbers
Viridian Therapeutics, Inc. (VRDN) reported revenue of $284K in Q2 2026 (quarter ended June 30, 2026), up 279% from the same quarter a year earlier. That came with net loss of $127M. For the full year FY2025, revenue was $71M (+23360% year on year) and net income −$343M. Its largest product in 2026-Q1 was Collaboration at $135K, 96% of the disclosed total, just ahead of License at 4.3%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $284K | $75K | +279% |
| Operating income | −$126M | −$107M | n/a |
| Net income | −$127M | −$101M | n/a |
| Diluted EPS | n/a | −$1.23 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Collaboration | $135K | 96% |
| License | $6K | 4.3% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $141.0K (-100%)
Collaboration grew +88% year on year
Segment Latestquarter on quarteryear on year
- Collaboration$135.0K$135.0KQoQ -76%year on year +88%-76%+88%
- License$6.0K$6.0KQoQ -100%year on year --100%-
- Collaboration--QoQ -year on year ---